These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7990448)

  • 81. Agreement between two measures of drug use in a low-prevalence population.
    Hancock L; Hennrikus D; Henry DA; Sanson-Fisher R; Walsh R; Lewis JH
    Addict Behav; 1991; 16(6):507-16. PubMed ID: 1801574
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Urine drug screening.
    Valentine JL; Farrar H; James L; Wells T; Simpson P
    J Clin Pharmacol; 1999 Apr; 39(4):425-7. PubMed ID: 10197302
    [No Abstract]   [Full Text] [Related]  

  • 83. Urine drug screening results from volunteers in phase I clinical pharmacology studies: are we being misled?
    Ramey KL; Kovacs SJ; Martin DE; Jorkasky DK
    J Clin Pharmacol; 1998 May; 38(5):413-6. PubMed ID: 9602952
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Is it necessary to confirm the results of drug screening with a 2d analytical method?].
    Vu Duc T; Vernay A
    Soz Praventivmed; 1986; 31(4-5):199-201. PubMed ID: 3532615
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Potential for false-positive results by the TRIAGE panel of drugs-of-abuse immunoassay.
    Poklis A; O'Neal CL
    J Anal Toxicol; 1996; 20(3):209-10. PubMed ID: 8735207
    [No Abstract]   [Full Text] [Related]  

  • 86. Analytical Methods Used for the Detection and Quantification of Benzodiazepines.
    Qriouet Z; Qmichou Z; Bouchoutrouch N; Mahi H; Cherrah Y; Sefrioui H
    J Anal Methods Chem; 2019; 2019():2035492. PubMed ID: 31583157
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Modification of Hewlett-Packard Chemstation (G1034C version C.02.00 and G1701AA version C.02.00 and C.03.00) data analysis program for addition of automatic extracted ion chromatographic groups.
    Amick GD
    J Anal Toxicol; 1998; 22(1):66-71. PubMed ID: 9491972
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Progress in chitin analytics.
    Tsurkan MV; Voronkina A; Khrunyk Y; Wysokowski M; Petrenko I; Ehrlich H
    Carbohydr Polym; 2021 Jan; 252():117204. PubMed ID: 33183639
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Beyond sensitivity, specificity and statistical independence.
    Jones RH; McClatchey MW
    Stat Med; 1988 Dec; 7(12):1289-95. PubMed ID: 3068763
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Chlorzoxazone mimics aprobarbital in Toxi-Lab Drug Screen.
    Breiner R; McComb R; Holtman V
    Clin Chem; 1984 Oct; 30(10):1719. PubMed ID: 6478611
    [No Abstract]   [Full Text] [Related]  

  • 91. Statistical properties of immunoanalytic system.
    Delaage M; Compiano JM; Barbet J; Artus A; Prince P
    J Immunol Methods; 1992 Jun; 150(1-2):103-10. PubMed ID: 1613247
    [No Abstract]   [Full Text] [Related]  

  • 92. Free research-based reference guide to drug abuse terms: two recent trends in Texas.
    Johnson J; Maxwell JC
    South Med J; 1999 Apr; 92(4):441-2. PubMed ID: 10219371
    [No Abstract]   [Full Text] [Related]  

  • 93. Importance of Urinary Drug Screening in the Multiple Sleep Latency Test and Maintenance of Wakefulness Test.
    Anniss AM; Young A; O'Driscoll DM
    J Clin Sleep Med; 2016 Dec; 12(12):1633-1640. PubMed ID: 27655451
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids.
    Berg JA; Schjøtt J; Fossan KO; Riedel B
    Subst Abuse Rehabil; 2015; 6():131-9. PubMed ID: 26604854
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Sample purification procedure for confirmation of 3'-hydroxy stanozolol by gas chromatography/high resolution mass spectrometry.
    Ahi S; Reddy IM; Beotra A; Lal R; Jain S; Kaur T
    Indian J Pharmacol; 2008 Aug; 40(4):164-9. PubMed ID: 20040950
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Drugs-of-abuse testing in urine: statistical approach and experimental comparison of immunochemical and chromatographic techniques.
    Ferrara SD; Tedeschi L; Frison G; Brusini G; Castagna F; Bernardelli B; Soregaroli D
    J Anal Toxicol; 1994 Sep; 18(5):278-91. PubMed ID: 7990448
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A multiple-site laboratory evaluation of three on-site urinalysis drug-testing devices.
    Crouch DJ; Frank JF; Farrell LJ; Karsch HM; Klaunig JE
    J Anal Toxicol; 1998 Oct; 22(6):493-502. PubMed ID: 9788525
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Optimization and validation of CEDIA drugs of abuse immunoassay tests in serum on Hitachi 912.
    Kirschbaum KM; Musshoff F; Schmithausen R; Stockhausen S; Madea B
    Forensic Sci Int; 2011 Oct; 212(1-3):252-5. PubMed ID: 21775079
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Evaluation of immunochemical drug screenings of whole blood samples. A retrospective optimization of cutoff levels after confirmation-analysis on GC-MS and HPLC-DAD.
    Kroener L; Musshoff F; Madea B
    J Anal Toxicol; 2003; 27(4):205-12. PubMed ID: 12820742
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Drug testing in the workplace.
    Phan HM; Yoshizuka K; Murry DJ; Perry PJ
    Pharmacotherapy; 2012 Jul; 32(7):649-56. PubMed ID: 22605533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.